Structure-based drug design (SBDD) stands at the forefront of drug discovery, emphasizing the creation of molecules that target specific binding pockets. Recent advances in this area have witnessed the adoption of deep generative models and geometric deep learning techniques, modeling SBDD as a conditional generation task where the target structure serves as context. Historically, evaluation of these models centered on docking scores, which quantitatively depict the predicted binding affinity between a molecule and its target pocket. Though state-of-the-art models purport that a majority of their generated ligands exceed the docking score of ground truth ligands in test sets, it begs the question: Do these scores align with real-world biological needs? In this paper, we introduce the delta score, a novel evaluation metric grounded in tangible pharmaceutical requisites. Our experiments reveal that molecules produced by current deep generative models significantly lag behind ground truth reference ligands when assessed with the delta score. This novel metric not only complements existing benchmarks but also provides a pivotal direction for subsequent research in the domain.
Virtual screening, which identifies potential drugs from vast compound databases to bind with a particular protein pocket, is a critical step in AI-assisted drug discovery. Traditional docking methods are highly time-consuming, and can only work with a restricted search library in real-life applications. Recent supervised learning approaches using scoring functions for binding-affinity prediction, although promising, have not yet surpassed docking methods due to their strong dependency on limited data with reliable binding-affinity labels. In this paper, we propose a novel contrastive learning framework, DrugCLIP, by reformulating virtual screening as a dense retrieval task and employing contrastive learning to align representations of binding protein pockets and molecules from a large quantity of pairwise data without explicit binding-affinity scores. We also introduce a biological-knowledge inspired data augmentation strategy to learn better protein-molecule representations. Extensive experiments show that DrugCLIP significantly outperforms traditional docking and supervised learning methods on diverse virtual screening benchmarks with highly reduced computation time, especially in zero-shot setting.